109 related articles for article (PubMed ID: 27055371)
1. Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study.
Narayan V; Hwang WT; Lal P; Rosen MA; Gallagher M; O'Dwyer PJ; Vaughn DJ
Clin Genitourin Cancer; 2016 Dec; 14(6):504-510. PubMed ID: 27055371
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Vaughn DJ; Hwang WT; Lal P; Rosen MA; Gallagher M; O'Dwyer PJ
Cancer; 2015 May; 121(9):1463-8. PubMed ID: 25522918
[TBL] [Abstract][Full Text] [Related]
3. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
4. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
Dickson MA; Schwartz GK; Keohan ML; D'Angelo SP; Gounder MM; Chi P; Antonescu CR; Landa J; Qin LX; Crago AM; Singer S; Koff A; Tap WD
JAMA Oncol; 2016 Jul; 2(7):937-40. PubMed ID: 27124835
[TBL] [Abstract][Full Text] [Related]
5. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA
Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233
[TBL] [Abstract][Full Text] [Related]
6. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P
Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy.
Rose TL; Chism DD; Alva AS; Deal AM; Maygarden SJ; Whang YE; Kardos J; Drier A; Basch E; Godley PA; Dunn MW; Kim WY; Milowsky MI
Br J Cancer; 2018 Oct; 119(7):801-807. PubMed ID: 30293995
[TBL] [Abstract][Full Text] [Related]
11. PD0332991 (palbociclib) for treatment of pediatric intracranial growing teratoma syndrome.
Schultz KA; Petronio J; Bendel A; Patterson R; Vaughn DJ
Pediatr Blood Cancer; 2015 Jun; 62(6):1072-4. PubMed ID: 25417786
[TBL] [Abstract][Full Text] [Related]
12. Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature.
Beddok A; Xu HP; Henry AA; Porte B; Fourquet A; Cottu P; Kirova Y
Br J Cancer; 2020 Sep; 123(6):905-908. PubMed ID: 32595213
[TBL] [Abstract][Full Text] [Related]
13. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
14. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
Owsley J; Jimeno A; Diamond JR
Drugs Today (Barc); 2016 Feb; 52(2):119-29. PubMed ID: 27092341
[TBL] [Abstract][Full Text] [Related]
15. Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).
Sepúlveda-Sánchez JM; Gil-Gil M; Alonso-García M; Vaz Salgado MÁ; Vicente E; Mesía Barroso C; Rodríguez Sánchez Á; Durán G; De Las Peñas R; Muñoz-Langa J; Velasco G; Hernández-Laín A; Hilario A; Navarro Martín M; Benavides M; Oleaga L; Cantero Montenegro D; Ruano Y; Sánchez-Gómez P; Martín-Soberón MC; Morales-Llombart R; Pachón V; Pineda E
Target Oncol; 2020 Oct; 15(5):613-622. PubMed ID: 33025213
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).
Van Mater D; Gururangan S; Becher O; Campagne O; Leary S; Phillips JJ; Huang J; Lin T; Poussaint TY; Goldman S; Baxter P; Dhall G; Robinson G; DeWire-Schottmiller M; Hwang EI; Stewart CF; Onar-Thomas A; Dunkel IJ; Fouladi M
Pediatr Blood Cancer; 2021 Apr; 68(4):e28879. PubMed ID: 33405376
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib ups PFS in HER2-/ER+ breast cancer.
Cancer Discov; 2014 Jun; 4(6):624-5. PubMed ID: 24891344
[No Abstract] [Full Text] [Related]
18. Safety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trials.
Guo L; Hu Y; Chen X; Li Q; Wei B; Ma X
Cancer Med; 2019 Apr; 8(4):1389-1400. PubMed ID: 30897298
[TBL] [Abstract][Full Text] [Related]
19. Blocking Cyclin-Dependent Kinase 4/6 During Single Dose Versus Fractionated Radiation Therapy Leads to Opposite Effects on Acute Gastrointestinal Toxicity in Mice.
Lee CL; Oh P; Xu ES; Ma Y; Kim Y; Daniel AR; Kirsch DG
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1569-1576. PubMed ID: 30056081
[TBL] [Abstract][Full Text] [Related]
20. Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer.
Anampa J; Haque T; Murakhovskaya I; Wang Y; Bachiashvili K; Papazoglu C; Pradhan K; Steidl UG; Sparano JA; Verma A
Haematologica; 2018 Mar; 103(3):e98-e102. PubMed ID: 29191840
[No Abstract] [Full Text] [Related]
[Next] [New Search]
